1
|
Gubareva EA, Golubev AG, Semenov AL, Yurova MN, Kruglov SS, Radetskaya EA. Effects of a Hydrolyzed Lignin Derivative on Bleomycin-Induced Pulmonary Fibrosis in Mice. Bull Exp Biol Med 2024; 177:39-43. [PMID: 38955853 DOI: 10.1007/s10517-024-06127-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2023] [Indexed: 07/04/2024]
Abstract
Female C57BL/J mice with pulmonary fibrosis induced by injections of bleomycin (20 mg/kg intraperitoneally, 8 times for 4 weeks) were treated with a lignin derivative-based composition BP-C3 (80 mg/kg, daily intragastric administrations for 4 weeks). Bleomycin treatment increased the severity of pulmonary fibrosis (Ashcroft score increased from 1.43±0.20 to 4.17±0.48) and the percentage of α-SMA+ tissue (from 15.22±1.01 to 33.12±2.30%) and DNA-synthetizing nuclei (from 1.05±0.14 to 3.38±0.375). After treatment with BP-C3, we observed a tendency to a decrease in Ashcroft score (to 3.40±0.51) and a significant decrease in the percentage of α-SMA+ tissue to 24.30±1.70%; the percentage of DNA-synthetizing nuclei decreased to a lesser extent (to 3.03±0.22%). These results suggest that BP-C3 has a moderate antifibrotic activity.
Collapse
Affiliation(s)
- E A Gubareva
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia.
| | - A G Golubev
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - A L Semenov
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - M N Yurova
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - S S Kruglov
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - E A Radetskaya
- N. N. Petrov National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| |
Collapse
|
2
|
Liao YF, Luo FL, Tang SS, Huang JW, Yang Y, Wang S, Jiang TY, Man Q, Liu S, Wu YY. Network analysis and experimental pharmacology study explore the protective effects of Isoliquiritigenin on 5-fluorouracil-Induced intestinal mucositis. Front Pharmacol 2022; 13:1014160. [PMID: 36278232 PMCID: PMC9582754 DOI: 10.3389/fphar.2022.1014160] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 09/20/2022] [Indexed: 11/21/2022] Open
Abstract
5-fluorouracil (5-FU) is one of the most widely used chemotherapy drugs for malignant tumors. However, intestinal mucositis caused by 5-FU is a severe dose-limiting toxic effect and even leads to treatment interruption. Isoliquiritigenin (ISL) is one of the main active compounds of licorice, which is a traditional Chinese herbal medicine commonly used in inflammation and gastrointestinal diseases. It is speculated that ISL have protective effects on intestinal mucositis. However, no such studies have been reported. Therefore, to investigate the impact of ISL on 5-Fu-induced intestinal mucositis, a strategy based on network prediction and pharmacological experimental validation was proposed in this study. Firstly, the targets and mechanism of ISL in alleviating 5-Fu-induced gastrointestinal toxicity were predicted by network analysis. And the results were further confirmed by molecular docking. Then, a mouse model of intestinal mucositis was established by intraperitoneal injection of 5-FU (384 μmol/kg) to verify the prediction of network analysis. The network analysis results suggested that PTGS2 (Prostaglandin G/H synthase 2) and NOS2 (Nitric oxide synthase, inducible) might be the critical targets of ISL for reducing the intestinal toxicity of 5-FU. In addition, KEGG and GO enrichment analysis revealed that the HIF-1, TNF, MAPK, IL-17, PI3K-Akt, Ras, NF-kappa B signaling pathway, and biological processes of the inflammatory response, apoptosis regulation, NO production and NF-kappa B transcription factor activity might be involved in the mechanism of ISL against intestinal mucositis. Subsequent animal experiments showed that ISL could reduce the weight loss, leukopenia and mucosal damage caused by 5-FU. Compared with the intestinal mucositis model, the protein expressions of PTGS2, NOS2, TNFα (Tumor necrosis factor-alpha) and NF-κB p65 (nuclear factor kappa-B P65) were decreased after ISL treatment. In conclusion, this study is the fist time to find that ISL can attenuate 5-FU-induced intestinal mucositis in mice. Its anti-mucositis effect may be through regulating TNF/NF-κB pathway and inhibiting inflammatory mediators PTGS2 and NOS2. It will provide a potential candidate for the prevention and treatment of chemotherapy-induced intestinal mucositis.
Collapse
Affiliation(s)
- Yi-fan Liao
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Feng-lin Luo
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Shan-shan Tang
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Jing-wei Huang
- Key Laboratory of Coarse Cereal Processing, Ministry of Agriculture and Rural Affairs, Sichuan Engineering & Technology Research Center of Coarse Cereal Industralization, Chengdu University, Chengdu, Sichuan, China
| | - Ying Yang
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Shuang Wang
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Tang-yu Jiang
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
| | - Qiong Man
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
- *Correspondence: Yi-ying Wu, ; Qiong Man, ; Sha Liu,
| | - Sha Liu
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
- *Correspondence: Yi-ying Wu, ; Qiong Man, ; Sha Liu,
| | - Yi-ying Wu
- Department of Pharmacology, School of Pharmacy, Chengdu Medical College, Chengdu, Sichuan, China
- Department of Pharmacy, Study on the Structure-Specific Small Molecule Drug in Sichuan Province College Key Laboratory, Chengdu Medical College, Chengdu, Sichuan, China
- *Correspondence: Yi-ying Wu, ; Qiong Man, ; Sha Liu,
| |
Collapse
|
3
|
A Use of Tritium-Labeled Peat Fulvic Acids and Polyphenolic Derivatives for Designing Pharmacokinetic Experiments on Mice. Biomedicines 2021; 9:biomedicines9121787. [PMID: 34944604 PMCID: PMC8698565 DOI: 10.3390/biomedicines9121787] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2021] [Revised: 11/23/2021] [Accepted: 11/26/2021] [Indexed: 11/30/2022] Open
Abstract
Natural products (e.g., polyphenols) have been used as biologically active compounds for centuries. Still, the mechanisms of biological activity of these multicomponent systems are poorly understood due to a lack of appropriate experimental techniques. The method of tritium thermal bombardment allows for non-selective labeling and tracking of all components of complex natural systems. In this study, we applied it to label two well-characterized polyphenolic compounds, peat fulvic acid (FA-Vi18) and oxidized lignin derivative (BP-Cx-1), of predominantly hydrophilic and hydrophobic character, respectively. The identity of the labeled samples was confirmed using size exclusion chromatography. Using ultra-high resolution Fourier transform ion cyclotron resonance mass spectrometry (FT ICR MS), key differences in the molecular composition of BP-Cx-1 and FA-Vi18 were revealed. The labeled samples ([3H]-FA-Vi18 (10 mg/kg) and [3H]-BP-Cx-1 (100 mg/kg)) were administered to female BALB/c mice intravenously (i.v.) and orally. The label distribution was assessed in blood, liver, kidneys, brain, spleen, thymus, ovaries, and heart using liquid scintillation counting. Tritium label was found in all organs studied at different concentrations. For the fulvic acid sample, the largest accumulation was observed in the kidney (Cmax 28.5 mg/kg and 5.6 mg/kg, respectively) for both routes. The organs of preferential accumulation of the lignin derivative were the liver (Cmax accounted for 396.7 and 16.13 mg/kg for i.v. and p.o. routes, respectively) and kidney (Cmax accounted for 343.3 and 17.73 mg/kg for i.v. and p.o. routes, respectively). Our results demonstrate that using the tritium labeling technique enabled successful pharmacokinetic studies on polyphenolic drugs with very different molecular compositions. It proved to be efficient for tissue distribution studies. It was also shown that the dosage of the polyphenolic drug might be lower than 10 mg/kg due to the sensitivity of the 3H detection technique.
Collapse
|
4
|
Iglesias-Carres L, Neilson AP. Utilizing preclinical models of genetic diversity to improve translation of phytochemical activities from rodents to humans and inform personalized nutrition. Food Funct 2021; 12:11077-11105. [PMID: 34672309 DOI: 10.1039/d1fo02782d] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Mouse models are an essential tool in different areas of research, including nutrition and phytochemical research. Traditional inbred mouse models have allowed the discovery of therapeutical targets and mechanisms of action and expanded our knowledge of health and disease. However, these models lack the genetic variability typically found in human populations, which hinders the translatability of the results found in mice to humans. The development of genetically diverse mouse models, such as the collaborative cross (CC) or the diversity outbred (DO) models, has been a useful tool to overcome this obstacle in many fields, such as cancer, immunology and toxicology. However, these tools have not yet been widely adopted in the field of phytochemical research. As demonstrated in other disciplines, use of CC and DO models has the potential to provide invaluable insights for translation of phytochemicals from rodents to humans, which are desperately needed given the challenges and numerous failed clinical trials in this field. These models may prove informative for personalized use of phytochemicals in humans, including: predicting interindividual variability in phytochemical bioavailability and efficacy, identifying genetic loci or genes governing response to phytochemicals, identifying phytochemical mechanisms of action and therapeutic targets, and understanding the impact of genetic variability on individual response to phytochemicals. Such insights would prove invaluable for personalized implementation of phytochemicals in humans. This review will focus on the current work performed with genetically diverse mouse populations, and the research opportunities and advantages that these models can offer to phytochemical research.
Collapse
Affiliation(s)
- Lisard Iglesias-Carres
- Plants for Human Health Institute, Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Kannapolis, NC, USA.
| | - Andrew P Neilson
- Plants for Human Health Institute, Department of Food, Bioprocessing and Nutrition Sciences, North Carolina State University, Kannapolis, NC, USA.
| |
Collapse
|
5
|
Panchenko AV, Fedoros EI, Pigarev SE, Maydin MA, Gubareva EA, Kireeva GS, Tyndyk ML, Kuznetsova AI, Nekhaeva TL, Danilova AB, Baldueva IA, Anisimov VN. The Effect of Polyphenolic Composition BP-C3 on the Efficacy and Hematological Toxicity of Cyclophosphamide in the Chemotherapy of Mice Bearing Soft Tissue Sarcomas Induced by Benzo[a]pyrene. Integr Cancer Ther 2019; 18:1534735419833778. [PMID: 30841763 PMCID: PMC7242777 DOI: 10.1177/1534735419833778] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
This study aimed to evaluate the effect of lignin-derived polyphenolic
composition BP-C3 on the efficacy and hematological toxicity of cyclophosphamide
(CPA). Male and female Swiss-H derived mice bearing benzo[a]pyrene-induced soft
tissue sarcomas were treated with CPA 300 mg/kg, BP-C3 75 mg/kg, or a
combination. Tumor growth inhibition in male mice treated with CPA, BP-C3, or a
combination of CPA and BP-C3 was significant and corresponded to 78%, 45%, and
82%, respectively, on day 21 after CPA administration on day 0. In female mice,
tumor growth inhibition was 58%, −11%, and 35% when treated with CPA, BP-C3, or
a combination of CPA and BP-C3, respectively. CPA administration resulted in
significant hematological toxicity evidenced by a decreased white blood cell
count on day 4 (2.43 ± 1.77 × 109/L in male mice and 1.19 ± 0.71 ×
109/L in female mice) and anemia development on day 7 (6.55 ±
1.74 × 1012/L in male mice and 5.89 ± 2.24 × 1012/L in
female mice). The red blood cell count measured on day 7 in animals treated with
the combination of BP-C3 and CPA constituted 7.12 ± 1.17 × 1012/L and
7.36 ± 2.07 × 1012/L for male and female mice, respectively. The
results of our study demonstrate the antitumor activity of BP-C3 in male mice
bearing soft tissue sarcomas. Neither the antitumor activity nor the
hematological toxicity of CPA were significantly influenced by BP-C3. A less
pronounced effect of CPA on RBC count is demonstrated when this agent is given
jointly with BP-C3.
Collapse
Affiliation(s)
- Andrey V Panchenko
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Elena I Fedoros
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia.,2 Nobel Ltd, Saint Petersburg, Russia
| | | | - Mikhail A Maydin
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Ekaterina A Gubareva
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Galina S Kireeva
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Margarita L Tyndyk
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | | | - Tatyana L Nekhaeva
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Anna B Danilova
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Irina A Baldueva
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| | - Vladimir N Anisimov
- 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia
| |
Collapse
|
6
|
Cruz-Nova P, Schnoor M, Correa-Basurto J, Bello M, Briseño-Diaz P, Rojo-Domínguez A, Ortiz-Mendoza CM, Guerrero-Aguirre J, García-Vázquez FJ, Hernández-Rivas R, Thompson-Bonilla MDR, Vargas M. The small organic molecule C19 binds and strengthens the KRAS4b-PDEδ complex and inhibits growth of colorectal cancer cells in vitro and in vivo. BMC Cancer 2018; 18:1056. [PMID: 30382908 PMCID: PMC6211466 DOI: 10.1186/s12885-018-4968-3] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 10/17/2018] [Indexed: 11/26/2022] Open
Abstract
BACKGROUND Colorectal cancer is the third most common cancer worldwide; and in 40% of all cases, KRAS4b-activating mutations occur. KRAS4b is transported by phosphodiesterase-6δ (PDEδ) to the plasma membrane, where it gets activated. PDEδ downregulation prevents redistribution and activation of KRAS4b. Thus, targeting the KRAS4b-PDEδ complex is a treatment strategy for colorectal cancer. METHODS Using docking and molecular dynamics simulations coupled to molecular mechanics, the generalized born model and solvent accessibility (MMGBSA) approach to explore protein-ligand stability, we found that the compound ((2S)-N-(2,5-diclorofenil)-2-[(3,4-dimetoxifenil)metilamino]-propanamida), termed C19, bound and stabilized the KRAS4b-PDEδ complex. We investigated whether C19 decreases the viability and proliferation of colorectal cancer cells, in addition to knowing the type of cell death that it causes and if C19 decreases the activation of KRAS4b and their effectors. RESULTS C19 showed high cytotoxicity in the colorectal cancer cell lines HCT116 and LoVo, with a stronger effect in KRAS-dependent LoVo cells. Importantly, C19 significantly decreased tumor size in a xenograft mouse model and showed lower side effects than 5-fluorouracil that is currently used as colorectal cancer treatment. CONCLUSIONS Mechanistically, the cytotoxic effect was due to increased apoptosis of tumor cells and decreased phosphorylation of Erk and Akt. Therefore, our results suggest that C19 may serve as a promising new treatment for colorectal cancer.
Collapse
Affiliation(s)
- Pedro Cruz-Nova
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. I.P.N, 2508, México City, Mexico
| | - Michael Schnoor
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. I.P.N, 2508, México City, Mexico
| | - José Correa-Basurto
- Laboratorio de Modelado Molecular y diseño de fármacos de la Escuela Superior de Medicina, Instituto Politécnico Nacional, México City, Mexico
| | - Martiniano Bello
- Laboratorio de Modelado Molecular y diseño de fármacos de la Escuela Superior de Medicina, Instituto Politécnico Nacional, México City, Mexico
| | - Paola Briseño-Diaz
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. I.P.N, 2508, México City, Mexico
| | - Arturo Rojo-Domínguez
- Departamento de Ciencias Naturales, Universidad Autónoma Metropolitana Unidad Cuajimalpa, México City, Mexico
| | - Carlos M Ortiz-Mendoza
- Investigación Biomédica y Traslacional, Laboratorio de Medicina Genómica, Hospital 1° de Octubre, ISSSTE, México City, Mexico
| | - Jorge Guerrero-Aguirre
- Investigación Biomédica y Traslacional, Laboratorio de Medicina Genómica, Hospital 1° de Octubre, ISSSTE, México City, Mexico
| | | | - Rosaura Hernández-Rivas
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. I.P.N, 2508, México City, Mexico
| | | | - Miguel Vargas
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-IPN), Av. I.P.N, 2508, México City, Mexico.
| |
Collapse
|
7
|
Fedoros EI, Orlov AA, Zherebker A, Gubareva EA, Maydin MA, Konstantinov AI, Krasnov KA, Karapetian RN, Izotova EI, Pigarev SE, Panchenko AV, Tyndyk ML, Osolodkin DI, Nikolaev EN, Perminova IV, Anisimov VN. Novel water-soluble lignin derivative BP-Cx-1: identification of components and screening of potential targets in silico and in vitro. Oncotarget 2018; 9:18578-18593. [PMID: 29719628 PMCID: PMC5915095 DOI: 10.18632/oncotarget.24990] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2017] [Accepted: 12/16/2017] [Indexed: 11/25/2022] Open
Abstract
Identification of molecular targets and mechanism of action is always a challenge, in particular – for natural compounds due to inherent chemical complexity. BP-Cx-1 is a water-soluble modification of hydrolyzed lignin used as the platform for a portfolio of innovative pharmacological products aimed for therapy and supportive care of oncological patients. The present study describes a new approach, which combines in vitro screening of potential molecular targets for BP-Cx-1 using Diversity Profile - P9 panel by Eurofins Cerep (France) with a search of possible active components in silico in ChEMBL - manually curated chemical database of bioactive molecules with drug-like properties. The results of diversity assay demonstrate that BP-Cx-1 has multiple biological effects on neurotransmitters receptors, ligand-gated ion channels and transporters. Of particular importance is that the major part of identified molecular targets are involved in modulation of inflammation and immune response and might be related to tumorigenesis. Characterization of molecular composition of BP-Cx-1 with Fourier Transform Ion Cyclotron Resonance Mass Spectrometry and subsequent identification of possible active components by searching for molecular matches in silico in ChEMBL indicated polyphenolic components, nominally, flavonoids, sapogenins, phenanthrenes, as the major carriers of biological activity of BP-Cx-1. In vitro and in silico target screening yielded overlapping lists of proteins: adenosine receptors, dopamine receptor DRD4, glucocorticoid receptor, serotonin receptor 5-HT1, prostaglandin receptors, muscarinic cholinergic receptor, GABAA receptor. The pleiotropic molecular activities of polyphenolic components are beneficial in treatment of multifactorial disorders such as diseases associated with chronic inflammation and cancer.
Collapse
Affiliation(s)
- Elena I Fedoros
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia.,Nobel LTD, Saint-Petersburg 192012, Russia
| | - Alexey A Orlov
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Alexander Zherebker
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia.,Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia
| | - Ekaterina A Gubareva
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia
| | - Mikhail A Maydin
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia
| | | | - Konstantin A Krasnov
- Institute of Toxicology, Federal Medical-Biological Agency, Saint-Petersburg 192019, Russia
| | | | | | | | - Andrey V Panchenko
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia
| | - Margarita L Tyndyk
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia
| | - Dmitry I Osolodkin
- Institute of Poliomyelitis and Viral Encephalitides, Chumakov FSC R&D IBP RAS, Moscow 108819, Russia.,Sechenov First Moscow State Medical University, Moscow 119991, Russia
| | - Evgeny N Nikolaev
- Skolkovo Institute of Science and Technology, Skolkovo 143025, Russia.,Institute for Energy Problems of Chemical Physics, Russian Academy of Sciences, Moscow 119334, Russia.,Orekhovich Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow 119121, Russia
| | - Irina V Perminova
- Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
| | - Vladimir N Anisimov
- N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg 197758, Russia
| |
Collapse
|